CNS Pharmaceuticals (CNSP) Return on Capital Employed (2019 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Return on Capital Employed came in at 260.14% in Q4 2025, up 930.0% YoY from 25.26% in Q4 2024, and down 121.29% on a QoQ basis from 117.55% in Q3 2025.
CNS Pharmaceuticals (CNSP) Return on Capital Employed (2019 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 7 years of Return on Capital Employed data on file, last reported at 260.14% in Q4 2025.
- Quarterly Return on Capital Employed rose 930.0% year-over-year to 260.14% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 260.14% (up 930.0% YoY) and the FY2025 annual result came in at 350.48%, up 20627.0% from the prior year.
- Return on Capital Employed slipped to 260.14% in Q4 2025, from 117.55% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 458.06% in Q4 2023 to a low of 5800.22% in Q3 2023.
- A 5-year average of 475.82% and a median of 142.6% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 565105 bps — and 2024, when it jumped 386432 bps.
- Tracing CNSP's Return on Capital Employed over 5 years: stood at 192.17% in 2021, then slipped by 24 bps to 237.61% in 2022, then jumped by 293 bps to 458.06% in 2023, then slumped by 159 bps to 269.44% in 2024, then climbed by 3 bps to 260.14% in 2025.
- The last three Return on Capital Employed figures came in at 260.14% (Q4 2025), 117.55% (Q3 2025), and 122.21% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | -260.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -260.14% |
| Sep 30, 2025 | -117.55% |
| Jun 30, 2025 | -122.21% |
| Mar 31, 2025 | -185.83% |
| Dec 31, 2024 | -269.44% |
| Sep 30, 2024 | -1,935.90% |
| Jun 30, 2024 | 340.29% |
| Mar 31, 2024 | 396.40% |
| Dec 31, 2023 | 458.06% |
| Sep 30, 2023 | -5,800.22% |
| Jun 30, 2023 | -596.23% |
| Mar 31, 2023 | -270.07% |
| Dec 31, 2022 | -237.61% |
| Sep 30, 2022 | -149.17% |
| Jun 30, 2022 | -111.03% |
| Mar 31, 2022 | -134.61% |
| Dec 31, 2021 | -192.17% |
| Sep 30, 2021 | -136.03% |
| Jun 30, 2021 | -104.83% |
| Mar 31, 2021 | -88.08% |